AMF Tjanstepension AB Has $10.75 Million Position in Axon Enterprise, Inc. (NASDAQ:AXON)

AMF Tjanstepension AB boosted its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 26.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,341 shares of the biotechnology company’s stock after buying an additional 7,233 shares during the quarter. AMF Tjanstepension AB’s holdings in Axon Enterprise were worth $10,745,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brookstone Capital Management increased its position in Axon Enterprise by 5.1% in the 1st quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 41 shares in the last quarter. HB Wealth Management LLC increased its position in Axon Enterprise by 3.9% in the 4th quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 43 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in Axon Enterprise by 1.1% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,997 shares of the biotechnology company’s stock valued at $1,033,000 after buying an additional 43 shares in the last quarter. UMB Bank n.a. increased its position in Axon Enterprise by 11.0% in the 4th quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 44 shares in the last quarter. Finally, Rise Advisors LLC increased its position in Axon Enterprise by 49.0% in the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 47 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AXON has been the subject of a number of recent research reports. Craig Hallum boosted their price objective on Axon Enterprise from $325.00 to $370.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Tuesday, May 7th. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Barclays boosted their target price on Axon Enterprise from $308.00 to $381.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. boosted their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research note on Thursday, April 11th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Axon Enterprise Trading Down 1.4 %

NASDAQ:AXON opened at $294.24 on Friday. The company has a market cap of $22.21 billion, a P/E ratio of 86.04 and a beta of 0.91. The stock’s fifty day moving average price is $295.25 and its two-hundred day moving average price is $284.70. Axon Enterprise, Inc. has a 1 year low of $175.37 and a 1 year high of $329.87. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.20. The firm had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The business’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.51 earnings per share. As a group, analysts expect that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total transaction of $279,747.96. Following the sale, the director now owns 4,553 shares in the company, valued at $1,282,671.16. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Julie A. Cullivan sold 993 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the transaction, the director now owns 4,553 shares of the company’s stock, valued at $1,282,671.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jeffrey C. Kunins sold 43,668 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $309.94, for a total transaction of $13,534,459.92. Following the completion of the transaction, the insider now directly owns 189,719 shares in the company, valued at approximately $58,801,506.86. The disclosure for this sale can be found here. Insiders have sold a total of 89,447 shares of company stock worth $27,684,677 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.